New combo for CLL with TP53 changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of three medications (epcoritamab, venetoclax, and ibrutinib) for people with untreated chronic lymphocytic leukemia (CLL) that has a TP53 alteration. The goal is to see if this triplet therapy is safe and effective for this specific type of CLL.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and younger than 80.
- You have been diagnosed with CLL or SLL that hasn't been treated before, and you need treatment now.
- Your CLL has a specific change in the TP53 gene (like a 17p deletion or TP53 mutation).
- You are not living with a serious heart condition, bleeding disorder, or other cancer that requires treatment.
- You are willing to use birth control and follow vaccination and testing schedules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests a combination of three drugs (nemtabrutinib, venetoclax, and obinutuzumab) for people with CLL or SLL who need treatment but haven't taken similar targeted therapies before. It aims to see if this new cocktail works better together.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
This trial tests whether combining three drugs (tafasitamab, acalabrutinib, and venetoclax) can better treat chronic lymphocytic leukemia or small lymphocytic lymphoma in patients who haven't received prior treatment. The goal is to see if this combination helps control the disease and improve outcomes.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.